Kumquat Biosciences Inc.

This early-stage trial tests an experimental drug called KQB548 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have a specific KRAS G12D mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 78 parti…

This study tests whether adding an experimental drug (KQB198) to the standard cancer pill imatinib can shrink or control advanced gastrointestinal stromal tumors (GIST). About 46 adults with a specific gene mutation (KIT or PDGFRA) will receive the combination. The goal is to see…

This early-phase study tests an experimental drug called KQB365 in adults with advanced solid tumors that have KRAS G12S or G12C mutations and haven't responded to standard treatments. The main goals are to find a safe dose and see if KQB365 alone or combined with other drugs can…

This early-stage trial tests a new oral drug, KQB168, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to immunotherapy. The main goals are to find safe doses and see if the drug can shrink tumors. About 84 participants will take the …

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will t…